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GUEST EDITORIAL
Chemotherapy for metastatic soft tissue sarcomas - another full circle?
V.H.C. Bramwell
Department Oncology, University of Western Ontario, London Regional Cancer Centre, 790 Commissioners Road, East London,
Ontario N6A 4L6, Canada.
After attending the sarcoma session of the 1990 meeting of
the American Society for Clinical Oncology, one might be
forgiven for wondering if chemotherapy for metastatic soft
tissue sarcoma (STS) has come a full circle. It is 18 years
since the South West Oncology Group (SWOG) published
results of the first large scale study of doxorubicin (ADR)
(O'Bryan et al., 1973). In 45 evaluable patients there were 13
complete and partial responses, giving an overall response
rate of 29%. Since that time a variety ofcombination chemo-
therapy regimens have been tested, with overall response
rates as high as 71% (Bodey et al., 1981). Yet, in the largest
randomised phase III trial ever performed in metastatic STS
(Santoro et al., 1990) the European Organisation for
Research and Treatment of Cancer (EORTC) has failed to
demonstrate superiority for combination chemotherapy, based
on cyclophosphamide or ifosfamide, compared with doxo-
rubicin alone. Why should this be, and does it mean we have
reached an impasse in the management of this disease, once
it is disseminated?
SWOG explored the addition of other agents to doxo-
rubicin in a logical sequence of studies (Gottlieb et al., 1975),
but individual regimens were not compared with each other
in randomised trials. The rationale for adding dacarbazine
(DIC) was its proven, although limited activity as a single
agent (Gottlieb et al., 1976). However, the addition of cyclo-
phosphamide (CYCLO) and vincristine (VCR) was purely
speculative based on the efficacy of these drugs in childhood
sarcomas.
This series of studies (Gottlieb et al., 1975) showed respec-
tive response rates of 31%, 42%, 42% and 55% for ADR
alone, ADIC, VADIC and CYVADIC (CYCLO + VCR +
ADR + DIC). Exclusion of bone tumours from the CYVADIC
study left a total of 118 patients with STS, in whom the
response rate was 59%. Since then, despite marginal activity
as single agents, other drugs such as actinomycin D (Ben-
jamin et al., 1976; Schoenfeld et al., 1982), cisplatinum
(Edmonson et al., 1983, 1985; Cormier et al., 1986) and
methotrexate (Bryant et al., 1980; Lynch et al., 1982; Pres-
grave et al., 1987) have been incorporated into ADR based
combinations. Although there were insignificant differences in
response rate and survival when actinomycin D (DACT) was
substituted for DIC in CYVADIC (Benjamin et al., 1976) in
a subsequent randomised trial of SWOG, other combinations
including DACT had limited activity (Schoenfeld et al.,
1982). Thus, in the late 1970's CYVADIC became a standard
treatment, and was the subject of at least ten large scale
studies (Bramwell, 1988).
Unfortunately other investigators were unable to repro-
duce the results achieved by SWOG for the CYVADIC
combination. Later response rates ranged from 20% (Giu-
liano et al., 1978) through 27% (Karakousis et al., 1982) and
39% (Pinedo et al., 1985) to 48% (Bui et al., 1985). In 1980,
Yap et al. reanalysed the SWOG data set from the first
CYVADIC study (Gottlieb et al., 1976). For 125 patients
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with STS deemed to be eligible, the overall response rate was
somewhat lower at 50%. Many investigators started to ques-
tion the contribution of CYCLO and VCR, and there was a
move back to ADR/DIC combinations, which permitted the
use of a slightly higher dose of ADR (60 mg m-2 vs 50 mg
m-2 in CYVADIC). Surprisingly ADIC has never been com-
pared directly with CYVADIC in a large scale randomised
trial.
ECOG carried out one of the earliest randomised studies
evaluating the efficacy of high dose ADR (70 mg m-2 every 3
weeks), in comparison with two combination chemotherapy
regimens (Schoenfeld et al., 1982). ADR was statistically
superior to VAC (VCR + DACT + CYCLO) with respective
response rates of 27% and 11%, confirming the lack of
efficacy of DACT containing combinations in adult STS.
Although the response rate for single agent ADR was higher
than the 19% achieved with the second combination regimen
(VCR + ADR + CYCLO) used in this study, the difference
was not significant. A later trial by SWOG, randomising 335
patients (Baker et al., 1987), showed that adding CYCLO or
DACT to the ADIC regimen did not significantly improve
response rates, which were respectively 33% (ADIC), 34%
(CYCLO/ADIC) and 24% (DACT/ADIC).
ECOG performed another three arm trial (Bordon et al.,
1987) in which patients were randomised to high dose ADR
as described above (Schoenfeld et al., 1982); or to ADR
20mg m2 dl,2,3 followed by 15 mg m-2 d8 and weekly
thereafter; or to ADIC. The response rate to ADIC was
significantly better at 30% (P<0.02), compared with 18%
and 16% for the 3 weekly and loading/weekly dose schedules
of ADR, although complete response rates, durations of
response and survival were similar for the three regimens.
The authors' conclusion questioning 'whether the increased
response frequency, without an impact on survival, is worth
the significantly greater toxicity' was criticised in an accom-
panying editorial (Benjamin, 1987), which suggested that
higher doses of ADIC incorporating Ifosfamide (IFOS) init-
ially or subsequently should be pursued. Another interesting
point, not commented on in the paper or editorial is that the
response rate in this second ECOG study, to the 3 weekly
schedule of ADR was low compared with the previous study,
18% vs 27%, although the dose/schedule was identical.
Because of variability in patient populations, direct com-
parisons between studies have limited value. However, a
response rate of 27% is in keeping with many other studies
of intermittent high dose ADR (Bramwell et al., 1983; Mou-
ridsen et al., 1987; Santoro et al., 1990), and is similar to the
respose rate for ADIC (30%) in this second ECOG trial
(Bordon et al., 1987) and for ADIC (33%) in the SWOG
trial (Baker et al., 1987).
Benjamin's editorial (1987) suggested that 'IFOS inten-
sification' might produce better results. IFOS had been syn-
thesised in Germany in the 1960's, and shown to have a
broad spectrum of activity, but a high incidence of haemorr-
hagic cystitis had discouraged its widespread use. The dis-
covery of Mesna, a sulphydryl donor, which neutralises the
toxic byproduct acrolein in the bladder, led to a re-evaluation
of IFOS in the 1980's, and promising results were reported
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for STS (Stuart-Harris et al., 1983; Bramwell et al., 1986;
Antman et al., 1989). Preliminary data suggested that re-
sponse rates between 25-35% could be achieved in patients
not previously exposed to chemotherapy. Such activity was
higher than that seen for any single agent other than ADR.
A randomised study (Bramwell et al., 1986) conducted by the
EORTC demonstrated that IFOS 5 g m-2 q 3 weeks was
more active than CYCLO 1.5 g m-2, but less myelosuppres-
sive and could be incorporated without dose reduction into
combination chemotherapy with 50-60mgm2 ADR.
US investigators chose to incorporate IFOS into the ADIC
combination, and early results for a high dose 96 h infusional
regimen, MAID, were extremely promising (Elias et al.,
1989), with an overall response rate of 47% in 108 evaluable
patients. European investigators omitted DIC and concent-
rated on ADR + IFOS combinations, often based on a more
convenient 36 h infusional schedule of IFOS/Mesna. Res-
ponse rates were somewhat lower, 22-38% (Mansi et al.,
1988; Cantwell et al., 1988; Schutte et al., 1990) but in the
same range as previous European experience for combination
chemotherapy in STS.
The critical test of these new IFOS combinations is direct
comparison with standard regimens such as ADR, ADIC
and CYVADIC, and the American Intergroup and the
EORTC have completed the appropriate studies. Preliminary
results (Antman et al., 1990) of the Intergroup trial compar-
ing ADIC with MAID, have shown no differences in re-
sponse rates or survival between the two arms. To date, this
study has only appeared in abstract form, with 268 of the
421 patients entered currently evaluable, and actual response
rates were not quoted. The EORTC study (Santoro et al.,
1990), which accrued 716 patients, reported response rates of
24% for ADR, 27% for ADR + IFOS and 28% for
CYVADIC, based on 549 patients currently evaluable. These
results were not significantly different, and curves of time to
relapse and survival overlapped. Combination chemotherapy
was significantly more toxic.
It is tempting to conclude from these data that single agent
ADR in doses of > 70 mg m-2 q 3 weeks should be the
standard treatment for patients wishing to receive palliative
chemotherapy outside a clinical trial. Prolonged infusions,
splitting the dose over several days, or weekly treatment, may
reduce toxicity but add to the inconvenience.
A corollary of this conclusion would be the recommenda-
tion that promising new treatments should be compared, at
the earliest opportunity, with high dose single agent ADR in
a randomised phase III setting.
In the research setting, should we continue to explore other
avenues, or are these results so depressing that we should
abandon the intense investigation of these rare tumours? I
remain optimistic that progress can be made. Strategies
should include:
(a) identification of new active agents, preferably with
novel structures and different modes of action and
toxicity;
(b) synthesis of analogues of current effective agents,
especially if the structural changes might enhance
activity;
(c) definition of improved/dose schedules which might
optimise activity particularly for new agents such as
IFOS;
(d) dose intensification which may be permitted by growth
factor support and
(e) novel approaches, exploiting discoveries in the rapidly
expanding field of molecular biology which improve
our understanding of patterns of failure and
mechanisms of drug resistance.
Studies are currently underway in most of these areas.
Drugs with novel structures should be tested in STS,
although the smaller potential market may not make this a
top priority for industry sponsored trials. Analogues of
anthracyclines and alkylating agents are obvious candidates
for testing in STS, but anti-folates are an additional interest-
ing group. Early reports (Subramanian & Wiltshaw, 1978) of
significant activity for MTX have not been substantiated
(Presgrave et al., 1987; Pfeffer et al., 1988), but the Canadian
Sarcoma Group (CSG) has reported that trimetrexate has
modest activity in previously untreated patients (Quirt et al.,
1988). Unfortunately, it seems unlikely that this drug will be
developed as an anticancer agent because of its limited
activity in other tumour types and unpredictable myelotox-
icity. Another promising anti-folate, 10-EDAM, is currently
being studied by the CSG. The limited efficacy of current
single agent and combination chemotherapy in STS, makes it
entirely feasible to propose single agent investigational drug
therapy to patients as first line therapy, with the option to
proceed to standard ADR, alone or in combination, if this
fails. German groups (Hilgard et al., 1983; Brade et al., 1985)
have led the field in exploring high and prolonged dose/
schedules of IFOS, but comnparative studies are lacking.
Strategy (d) has been pursued by the EORTC, which has
used GM-CSF to permit dose intensification of ADR +
IFOS, escalating ADR to 75 mg m2. Early results (unpub-
lished) are promising, and a randomised trial comparing this
dose escalated regimen with standard dose ADR + IFOS will
soon be initiated. This approach has similarities to that
reported by Bodey et al. in 1981, who administered escalated
doses of CYVADIC in the setting of a protected environ-
ment-prophylactic antibiotic program. In a small group of
patients, a higher response rate (71%) was achieved and,
despite profound myelosuppression, infective episodes were
no more frequent than with standard therapy. Although it
achieved its objectives, the inconvenience and costs of such a
program in a palliative setting have limited its use. It remains
to be seen whether GM-CSF regimens will prove to be of
benefit, and cost-effective in this setting.
There have been many interesting findings relevant to STS
in the field of molecular biology. Specific chromosomal
breaks have been associated with particular subtypes of sar-
comas (Karakousis et al., 1987), over expression of the
MDR-1 gene may be linked with resistance to certain chemo-
therapeutic drugs (Gerlach et al., 1987; Chan et al., 1990)
and other mechanisms of resistance are being explored.
Different levels of oncogene expression may have a bearing
on the behaviour of STS (Fahrer et al., 1989; Kato et al.,
1990) and further elucidation of these patterns might gives us
clues to alternative treatment strategies.
In conclusion, identification of substantially more active
drugs or combination chemotherapy will provide not only a
better means of palliating metastatic disease, but might also
have the potential to cure patients if used appropriately as
adjuvant treatment.
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